Case Study

Advancing therapeutics for myeloma

Format: PDF file | Document type: Case Study | Promoted Content

This content is provided by Recipharm AB, and any views and opinions expressed do not necessarily reflect those of


Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement for more efficient and tolerable therapies.

Oncopeptides, a clinical stage company, has partnered with Recipharm's analytical chemistry team to help take a promising molecule from the discovery phase to clinical trials, with the end goal of commercial production. Download the full case study to read more about the project and Recipharm's development services.

Latest content from Recipharm AB


Content provided by Recipharm AB

Take steps to stay in the serialization race

As the deadline for drug serialization in the EU looms closer, it’s time to put the topic firmly on your agenda. Learn how to overcome the serialization challenge and simplify compliance.

Related resources from Recipharm AB

Show more

Supplier info centre